Sentences with phrase «in immune responses against tumors»

A T - cell marker panel that can identify subsets of tumor - associated T - cells allows scientists to identify and target subpopulations of T - cells playing unique roles in the immune response against a tumor.

Not exact matches

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

C. novyi is really a two - pronged weapon against cancer: It germinates in tumors and releases cancer - killing enzymes, and it may also trigger an immune response similar to Coley's Toxin.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

Now, scientists have modified Salmonella bacteria to trigger a particularly powerful immune response against human cancer cells implanted in mice, shrinking the tumors and — for the first time — preventing them from metastasizing.

They used the gene - editing CRISPR / Cas9 technique to sift the genomes of melanoma cells for changes that made tumors resistant to being killed by immune T cells, which are the main actors in the immune system response against infections and cancer cells.

These types of engineered tumors are much more difficult to treat than human tumors implanted in mice, because they suppress the immune response against them.

In 2008, he joined the group of Caetano Reis e Sousa at the Cancer Research UK (CRUK) London Research Institute and later joined the Francis Crick Institute, where he was awarded Marie Curie and EMBO long - term postdoctoral fellowships to investigate innate immune receptors and signaling pathways that trigger dendritic cell activation and drive T - cell responses against viruses or tumors.

In experiments in animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cellIn experiments in animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cellin animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cells.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

In different contexts, viruses appear capable of attacking tumors in a number of different ways — by directly infecting them, by releasing tumor proteins that trigger a broad immune response against the cancer, and by damaging the blood supply tumors need to survivIn different contexts, viruses appear capable of attacking tumors in a number of different ways — by directly infecting them, by releasing tumor proteins that trigger a broad immune response against the cancer, and by damaging the blood supply tumors need to survivin a number of different ways — by directly infecting them, by releasing tumor proteins that trigger a broad immune response against the cancer, and by damaging the blood supply tumors need to survive.

She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.

The TCGA analysis showed tumors with PTEN loss in the background of BRCA1 / 2 deficiency had lower levels of cytolytic immune molecules and immune - activating pathways that would normally drive immune responses against tumors.

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

Also, CMB305 was well tolerated, and generated a strong and broad anti-NY-ESO-1 immune response in > 50 % of the patients, including evidence of antigen spreading — the induction of an immune response against other tumor antigens not targeted by CMB305.

Induction of immune responses in patients with b - cell lymphoma against the surface - immunoglobulin idiotype expressed by their tumors